Aprecia, a US-based company that deals with 3DP technology for commercial-scale pharmaceutical manufacturing, announced on Wednesday that it has named Andrew Karazim as its new chief commercial officer.

In the new role, Karazim is to head the company's Commercialisation efforts. He will manage development and implementation of the company's commercialisation with broad responsibility for Strategy, Marketing, Business Development and Alliance Management.

Karazim has over 25 years of pharmaceutical and biotechnology experience with expertise across sales, marketing and market access. He has served in leadership roles at Lilly, Abbott and Kaleo. He has most recently served as the head of Market Access at Kaleo. He has held the position of general manager for Abbott Diabetes Care. He has served for first 22 years of his career at Lilly in a various Commercial leadership position in the US and globally.